Chi siamo Contatti Interazioni: 118 620
Cercare il medicinale per il nome

Amikin e Disfunzione renale

Risultato del controllo d'interazione tra il farmaco Amikin e la malattia Disfunzione renale su sicurezza in caso d'uso simultaneo.

Risultato di controllo:
Amikin <> Disfunzione renale
Rilevanza: 23.07.2019 Recensore: P.M. Shkutko, dott., in

Durante il controllo d'interazione, secondo le fonti autorevoli Drugs.com, Rxlist.com, Webmd.com, Medscape.com sono trovate le controindicazioni o gli effetti collaterali che possono danneggiare oppure intensificare l’effetto negativo in caso d'uso del farmaco in presenza di questa malattia concomitante.

Consumatore:

Gli aminoglicosidi sono potenzialmente oto - e nefrotossici. Ottavo nervo cranico danno può manifestarsi come vestibolare e/o uditiva, la tossicità, tra cui vertigini, nistagmo, vertigini, atassia, tinnito, e vari gradi di compromissione dell'udito. La nefrotossicità è di solito evidenziato da necrosi tubulare; un aumento del BUN, nonprotein di azoto, e la concentrazione di creatinina sierica; diminuisce di peso specifico delle urine e della clearance della creatinina; proteinuria; e le cellule o getta nelle urine. Raramente, renale, elettroliti sprecare può verificarsi, con conseguente ipocalcemia, ipomagnesemia, e ipokaliemia che possono essere associati con parestesia, tetania, confusione, e positivo Chvostek e Corredo di segni. Anche se la nefrotossicità indotta da aminoglicoside è generalmente reversibili dopo l'interruzione del farmaco, morte da uremia si è verificato raramente. La terapia con aminoglicosidi devono essere somministrati con cautela a dosaggi ridotti in pazienti con insufficienza renale, in quanto essi possono essere ad aumentato rischio per oto - e nefrotossicità a causa di accumulo del farmaco. Per ridurre al minimo il rischio di tossicità, i pazienti devono essere adeguatamente idratati, il solito aminoglicoside dosaggio non deve essere superato, l'uso con altri neuro - agenti nefrotossici deve essere evitato, e di picco e di depressione siero aminoglicoside concentrazioni devono essere periodicamente determinato e il dosaggio corretto per mantenere il livello desiderato. Renale e ottavo nervo cranico funzione devono essere attentamente monitorati e il dosaggio ridotto o terapia ritirata se la tossicità si sviluppa.

Fonte
  • Kumin GD "Clinical nephrotoxicity of tobramycin and gentamicin." JAMA 244 (1980): 1808-10
  • Jaffe, Meyers BR, Hirschman SZ "Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis." Antimicrob Agents Chemother 5 (1974): 611-6
  • Contreras AM, Gamba G, Cortes J, et al "Serial trough and peak amikacin levels in plasma as predictors of nephrotoxicity." Antimicrob Agents Chemother 33 (1989): 973-6
  • American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
  • Sarubbi FA, Hull JH "Amikacin serum concentrations: prediction of levels and dosage guidelines." Ann Intern Med 89 (1978): 612-8
  • "Product Information. Garamycin (gentamicin)." Schering-Plough Corporation, Kenilworth, NJ.
  • "Product Information. Streptomycin (streptomycin)." Pfizer US Pharmaceuticals, New York, NY.
  • Matzke GR, Millikin, Kovarik JM "Variability in pharmacokinetic values for gentamicin, tobramycin, and netilmicin in patients with renal insufficiency." Clin Pharm 8 (1989): 800-6
  • Matz GJ, Naunton RF "Ototoxic drugs and poor renal function." JAMA 206 (1968): 2119
  • French MA, Cerra FB, Plaut ME, Schentag JJ "Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients." Antimicrob Agents Chemother 19 (1981): 147-52
  • Pedersen SS, Jensen J, Osterhammel D, Osterhammel P "Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis." Antimicrob Agents Chemother 31 (1987): 594-9
  • Fanning WL, Gump D, Jick H "Gentamicin and cephalothin-associated rises in blood urea nitrogen." Antimicrob Agents Chemother 10 (1976): 80-2
  • Craig WA, Gudmundsson S, Reich RM "Netilmicin sulfate: a comparative evaluation of antimicrobial activity, pharmacokinetics, adverse reactions and clinical efficacy." Pharmacotherapy 3 (1983): 305-15
  • Humbert G, Leroy A, Fillastre JP, Oksenhendler G "Pharmacokinetics of netilmicin in the presence of normal or impaired renal function." Antimicrob Agents Chemother 14 (1978): 40-4
  • Kunin CM, Finland M "Persistence of antibiotics in blood of patients with acute renal failure. III. Penicillin, streptomycin, erythromycin and kanamycin." J Clin Invest 38 (1959): 1509-19
  • Smith CR, Lipsky JJ, Laskin OL, et al "Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin." N Engl J Med 302 (1980): 1106-9
  • Pijck J, Hallynck T, Soep H, Baert L, Daniels R, Boelaert J "Pharmacokinetics of amikacin in patients with renal insufficiency: relation of half-life and creatinine clearance." J Infect Dis 134 (1976): s331-41
  • Letona JM, Barbolla L, Frieyro E, et al "Immune haemolytic anaemia and renal failure induced by streptomycin." Br J Haematol 35 (1977): 561-71
  • "Product Information. Mycifradin (neomycin)." Emerson Laboratories, Texarkana, TX.
  • "Product Information. Nebcin (tobramycin)." Lilly, Eli and Company, Indianapolis, IN.
  • Herrero A, Alarco FR, Diez JM, Mahiques E, Domingo JV "Pharmacokinetics of netilmicin in renal insufficiency and hemodialysis." Int J Clin Pharmacol Ther Toxicol 26 (1988): 84-7
  • Madhavan T, Yaremchuk K, Levin N, et al "Effect of renal failure and dialysis on the serum concentration of the aminoglycoside amikacin." Antimicrob Agents Chemother 10 (1976): 464-5
  • Wilkinson R, Lucas GL, Heath DA, et al "Hypomagnesaemic tetany associated with prolonged treatment with aminoglycosides." Br Med J 292 (1986): 818-9
  • Luft FC, Brannon DR, Stropes LL, Costello RJ, Sloan RS, Maxwell DR "Pharmacokinetics of netilmicin in patients with renal impairment and in patients on dialysis." Antimicrob Agents Chemother 14 (1978): 403-7
  • "Product Information. Amikin (amikacin)." Bristol-Myers Squibb, Princeton, NJ.
  • Keys TF, Kurtz SB, Jones JD, Muller SM "Renal toxicity during therapy with gentamicin or tobramycin." Mayo Clin Proc 56 (1981): 556-9
  • Yoshikawa TT, Nagami PH "Adverse drug reactions in TB therapy: risks and recommendations." Geriatrics 37 (1982): 61-3, 67-8
  • Federspil P, Schatzle W, Tiesler E "Pharmacokinetics and ototoxicity of gentamicin, tobramycin and amikacin." J Infect Dis 134 (1976): s200-5
  • Siegenthaler WE, Bonetti A, Luthy R "Aminoglycoside antibiotics in infectious diseases: an overview." Am J Med 80 (1986): 2-14
  • McQueen EG "Antibiotic allergy and acute renal failure." N Z Med J 64 (1965): 561-3
  • Bergeron MG, Lessard C, Ronald A, Stiver G, Van Roogen CE, Chadwick P "Three to eight weeks of therapy with netilmicin: toxicity in normal and diabetic patients." J Antimicrob Chemother 12 (1983): 245-8
  • Emanuelli G, Anfossi G, Calcamuggi G, Marcarino C, Lanzio M "Urinary enzyme release following aminoglycoside administration in single low dose." Enzyme 39 (1988): 119-22
  • Williams PJ, Hull JH, Sarubbi FA, Rogers JF, WArgin WA "Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin." J Clin Pharmacol 26 (1986): 79-86
  • Solberg CO, Madsen ST, Digranes A, et al "High dose netilmicin therapy: efficacy, tolerance and tissue penetration." J Antimicrob Chemother 6 (1980): 133-41
  • Ristuccia AM, Cunha BA "The aminoglycosides." Med Clin North Am 66 (1982): 303-12
  • Lerner SA, Schmitt BA, Seligsohn R, Matz G "Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin." Am J Med 80 Suppl 6 (1986): 98-104
  • Gyselnyck AM, Forrey A, Cutler R "Pharmacokinetics of gentamicin: distribution and plasma and renal clearance." J Infect Dis 124 (1971): s70
  • Bock BV, Edelstein PH, Meyer RD "Prospective comparative study of efficacy and toxicity of netilmicin and amikacin." Antimicrob Agents Chemother 17 (1980): 217-25
  • "Product Information. Netromycin (netilmicin)." Schering Laboratories, Kenilworth, NJ.
  • Trollfors B, Alestig K, Krantz I, Norrby R "Quantitative nephrotoxicity of gentamicin in nontoxic doses." J Infect Dis 141 (1980): 306-9
  • Bhattacharya BK, Gorringe H, Farr MJ "Netilmicin and nephrotoxicity." Lancet 2 (1983): 216-7
  • Pines A, Goldhammer E, Kaplinsky N, Frankl O "Hypopotassemia associated with tobramycin treatment." Infection 10 (1982): 101-
  • Pechere JC, Dugal R, Pechere MM "Pharmacokinetics of netilmicin in renal insufficiency and haemodialysis." Clin Pharmacokinet 3 (1978): 395-406
  • Cimino MA, Rotstein C, Slaughter RL, Emrich LJ "Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy." Am J Med 83 (1987): 1091-7
  • Gatell JM, SanMiguel JG, Araujo V, et al "Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin." Antimicrob Agents Chemother 26 (1984): 766-9
  • Schentag JJ, Lasezkay G, Cumbo TJ, et al "Accumulation pharmacokinetics of tobramycin." Antimicrob Agents Chemother 13 (1978): 649-56
  • Russo ME, Atkin-Thor E "Gentamicin and ticarcillin in subjects with end-stage renal disease." Clin Nephrol 15 (1981): 175-80
  • McHenry MC, Wagner JG, Hall PM, Vidt DG, Gavan TL "Pharmacokinetics of amikacin in patients with impaired renal function." J Infect Dis 134 Suppl (1976): s343-54
  • Plantier J, Forrey AW, O'Neill MA, Blair AD, Christopher TG, Cutler RE "Pharmacokinetics of amikacin in patients with normal or impaired renal function: radioenzymatic acetylation assay." J Infect Dis 134 Suppl (1976): s323-30
  • Dahlgren JG, Anderson ET, Hewitt WL "Gentamicin blood levels: a guide to nephrotoxicity." Antimicrob Agents Chemother 8 (1975): 58-62
  • Tablan OC, Reyes MP, Rintelmann WF, Lerner AM "Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis." J Infect Dis 149 (1984): 257-63
  • Gilbert DN, Bennett WM "Use of antimicrobial agents in renal failure." Infect Dis Clin North Am 3 (1989): 517-31
  • Schentag JJ, Cerra FB, Plaut ME "Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients." Antimicrob Agents Chemother 21 (1982): 721-6
  • Bernstein JM, Gorse GJ, Linzmayer MI, et al "Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients." Arch Intern Med 146 (1986): 2329-34
  • Watson AJ, Watson MM, Keogh JA "Metabolic abnormalities associated with tobramycin therapy." Isr J Med Sci 153 (1984): 96-9
  • Beauchamp D, Gourde P, Theriault G, Bergeron MG "Age-dependent gentamicin experimental nephrotoxicity." J Pharmacol Exp Ther 260 (1992): 444-9
  • Contrepois A, Brion N, Garaud JJ, et al "Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans." Antimicrob Agents Chemother 27 (1985): 520-4
Amikin

Nome generico: amikacin

Marchio commerciale: Amikin, Amikin Pediatric

Sinonimo: non c`è

Interazione con cibo e stile di vita
Interazioni farmacologiche